{
    "nct_id": "NCT04017819",
    "official_title": "Biodistribution and Pharmacokinetic Study of the Positron Emission Tomography (PET) Radiopharmaceutical [18F]-C-SNAT4",
    "inclusion_criteria": "* ANC ≥ 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab assessment\n* Hgb ≥ 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb corrected to ≥ 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan\n* Platelet count ≥ 100 x 109/L w/o blood transfusions for 7 days preceding lab assessment\n* Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for pts with documented history of Gilbert's disease\n* ALT ≤ 2.5 x ULN\n* AST ≤ 2.5 x ULN\n* Alkaline phosphatase (AP) ≤ 3 x ULN\n* If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)\n* Karnofsky Performance Status (KPS) ≥ 60\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has already begun non-surgical therapy for any recurrence, prior to the first [18F]-C-SNAT4 PET/CT scan\n* Severe/uncontrolled inter-current illness within the previous 28 days prior to PET scan.\n* Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.\n* History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biological composition to [18F]-C-SNAT4 used in study.\n* Pregnant or nursing\n* Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).",
    "miscellaneous_criteria": ""
}